伊立替康联合卡培他滨二线治疗38例晚期结直肠癌的临床观察  

The combination of capecitabine and irinotecan in treating 38 cases of advanced colorectal cancer as second-line chemtherapy regimen

作　　者：耿梅[1] 马韬[1] 徐昊平[1] 楼谷音[1] 蒋劲松[1] 奚文崎[1] 黎皓[1] 曹卫国[1] 金冶宁[1] 

机构地区：[1]上海交通大学附属瑞金医院肿瘤放化疗科,上海200025

出　　处：《现代肿瘤医学》2009年第7期1305-1307,共3页Journal of Modern Oncology

摘　　要：目的:观察伊立替康联合卡培他滨二线治疗晚期结直肠癌的疗效及不良反应。方法:38例晚期结直肠癌患者予以伊立替康200mg/m2,第1天,口服卡培他滨1000mg/m2一日两次,联用14天,每21天重复,至少治疗2周期。结果:本组患者有效率7.9%(3/38),疾病控制率55.3%(21/38),其中部分缓解(PR)3例,稳定(SD)18例,进展(PD)17例。中位进展时间(TTP)及中位总生存期分别为4月和11月,临床疗效是影响TTP及OS的主要预后因素。3度以上不良反应主要为中性粒细胞减少(18.4%)及腹泻(10.5%)。结论:伊立替康联合卡培他滨二线治疗晚期结直肠癌具有良好的疗效与耐受性。Objective：To observe and evaluate the efficacy and adverse events of the combination of irinotecan plus capecitabine in the treatment of advanced colorectal cancer as second - line regimen. Methods ： Thirty - eight advanced colorectal cancer received a dose of 200mg/m^2 irinotecan on d1 , and an oral dose of 1000mg/m^2 capecitabine twice daily on d1 -14, every 3 weeks, at least two cycles were given for each patient. Results： The overall response rate was 7.9 % （3/38）, the disase control rate was 55.3 % （21/38）, including 3 partial response （ PR）, 18 stable disease（SD） and 17 progression （PD）. The median time to progression （TIP） and the median overall survival （OS） was 4 months and 11 months respectively,and clinical response was the important prognostic factor of time to progression and overall survival. Neutropenia （ 18.4% ） and diarrhea （ 10.5% ） were the most commonly observed grade 3 or 4 adverse events. Conclusion： Irinotecan combined with capecitabine as second - line regimen is efficacious and well - tolerated for the treatment of advanced colorectal cancer.

关 键 词：伊立替康 卡培他滨 二线化疗 晚期结直肠癌 

分 类 号：R730.53[医药卫生—肿瘤]